

This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims:

1. (Currently Amended) A compound from 12 to 50 nucleobases in length targeted to a nucleic acid molecule encoding growth hormone receptor, wherein said compound; comprises at least an 8-nucleobase portion of SEQ ID NO: 19; comprises deoxynucleotides in a first region, at least one high affinity modified sugar in each of a second region and a third region, which flank the first region on the 5' end and the 3' end, respectively; is at least 70% complementary with SEQ ID NO: 4; and specifically hybridizes with said nucleic acid molecule encoding growth hormone receptor (SEQ ID NO: 4).

2. (Canceled)

3. (Original) A compound according to claim 1 which is from 15 to 30 nucleobases in length.

4. (Original) A compound according to claim 1 comprising an oligonucleotide.

5. (Original) A compound according to claim 4 in which the oligonucleotide is an antisense oligonucleotide.

6. (Original) A compound according to claim 4 in which the oligonucleotide is a DNA oligonucleotide.

7. (Original) A compound according to claim 4 in which the oligonucleotide is a RNA oligonucleotide.

8. (Canceled)

9. (Original) A compound according to claim 7 which is a short interfering RNA (siRNA) molecule.

10. (Canceled)

11. (Previously Presented) A compound according to claim 1 comprising at least 80% complementarity with the nucleic acid molecule encoding growth hormone receptor (SEQ ID NO: 4).

12. (Previously Presented) A compound according to claim 1 comprising at least 90% complementarity with the nucleic acid molecule encoding growth hormone receptor (SEQ ID NO: 4).

13. (Previously Presented) A compound according to claim 1 comprising at least 95% complementarity with the nucleic acid molecule encoding growth hormone receptor (SEQ ID NO: 4).

14.-19. (Canceled)

20. (Currently Amended) A compound according to claim 1 further comprising at least one modified internucleoside linkage, ~~sugar moiety~~, nucleobase, or combination thereof.

21. (Currently Amended) A compound according to claim [[20]] 1 wherein the high affinity modified sugar is comprising at least one 2'-O-methoxyethyl, locked nucleic acid or ethylene-bridged nucleic acid ~~sugar moiety~~.

22. (Previously Presented) A compound according to claim 20 comprising at least one phosphorothioate internucleoside linkage.

23. (Previously Presented) A compound according to claim 20 comprising at least one 5-methylcytosine.

24.-45. (Canceled)

46. (Previously Presented) An antisense oligonucleotide comprising a nucleobase sequence of SEQ ID NO: 19 and further comprising a ten deoxynucleotide region flanked on both the 5' and the 3' ends with five 2'-O-(2 methoxyethyl) nucleotides, wherein each internucleoside linkage is a phosphorothioate and each cytosine is a 5-methylcytosine.

47. (Previously Presented) A pharmaceutical composition comprising the antisense oligonucleotide of claim 46 and a composition selected from the group consisting of a pharmaceutically acceptable carrier, diluent, penetration enhancer, excipient or combinations thereof.

48. (Currently Amended) An antisense oligonucleotide that specifically hybridizes with a region of SEQ ID NO: 4, wherein the region comprises at least an 8-nucleobase portion of SEQ ID NO:161 and wherein the compound comprises deoxynucleotides in a first region, at least one high affinity modified sugar in each of a second region and a third region, which flank the first region on the 5' end and the 3' end, respectively; and is at least 70% complementary with SEQ ID NO: 4.

49. (Currently Amended) An antisense oligonucleotide that specifically hybridizes with a region of SEQ ID NO: 4, wherein the region comprises SEQ ID NO: 161 and wherein the compound comprises deoxynucleotides in a first region, at least one high affinity modified sugar in each of a second region and a third region, which flank the first region on the 5' end and the 3' end, respectively; and is at least 70% complementary with SEQ ID NO: 4.

50. (New) A compound from 12 to 50 nucleobases in length targeted to a nucleic acid molecule encoding growth hormone receptor, wherein said compound comprises at least 12 consecutive nucleobases from SEQ ID NO: 19 and is at least 95% complementary with SEQ ID NO: 4.

51. (New) The compound of claim 50 comprising 100% complementarity with SEQ ID NO: 4.

52. (New) The compound of claim 50 comprising at least one of a modified internucleoside linkage, a high affinity modified sugar or a modified nucleobase.

53. (New) The compound of claim 52 having at least one 2'-O-methoxyethyl sugar moiety.

54. (New) The compound of claim 52 having at least one phosphorothioate internucleoside linkage.

55. (New) The compound of claim 52 having at least one 5-methylcytosine.

56. (New) The compound of claim 52 that is a pharmaceutically acceptable salt.

57. (New) The compound of claim 50 that is a pharmaceutically acceptable salt.